Wave Life Sciences' Stock Falls: Investigational Therapy Fails To Show Clinical Benefit In Rare Neurological Diseases
Portfolio Pulse from Vandana Singh
Wave Life Sciences announced that its investigational treatment WVE-004 for C9orf72-associated ALS and FTD failed to show clinical benefit in the Phase 1b/2a FOCUS-C9 study. The company will discontinue the development of WVE-004. Wave's stock fell 15.10% in premarket trading.
May 23, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wave Life Sciences' stock fell after its investigational treatment WVE-004 failed to show clinical benefit in a Phase 1b/2a study for rare neurological diseases.
Wave Life Sciences' stock fell 15.10% in premarket trading after the company announced that its investigational treatment WVE-004 failed to show clinical benefit in the Phase 1b/2a FOCUS-C9 study for C9orf72-associated ALS and FTD. The company will discontinue the development of WVE-004, which negatively impacts the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100